Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Bactroban, Centany (1)

Analgesic (2) · Classic Psychedelic (1) · Lysergamide (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[:Category:Antibacterials|Antibacterial]] (1) · [[:Category:Topical_antibiotics|Topical antibiotic]] (1)

Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of LSD; 5-HT2A agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000009FF-QINU`"', '"`UNIQ--vote-00000A00-QINU`"', '"`UNIQ--vote-00000A01-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days (1)

None (2) · 2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · Limit topical to 10-day courses to reduce resistance pressure (1)

None (2) · intranasal (1) · PO (only formulation marketed in the US). (1) · Topical (1)

None (2) · 30–60 min (PO) (1) · Days (1)

None (2) · 4–6 hours (1) · Hours per application (1)

None (2) · 2.5–3 hours (1) · Not meaningfully described for topical use'"`UNIQ--ref-00000A02-QINU`"' (1)

None (2) · Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)